Kate Hurtig

Kate Hurtig currently serves as General Manager and Head of Cluster for the UK, Ireland, and Nordics at Grünenthal Group, where responsibilities include the global commercialization of innovative assets and the leadership of various strategic functions within the organization. Kate has held multiple senior roles, including Global Head of Innovative Medicines and SVP, Head of Global Portfolio Commercialization. Prior to Grünenthal, Kate Hurtig Consulting Limited was established to provide expertise in commercial strategy and global marketing. Previous experience includes leading significant commercial efforts at Mundipharma International Limited and Amgen, where notable achievements include successful product launches and strategic brand development in the pharmaceutical sector. Educational qualifications include an MBA from London Business School and a B.Sc. in physiology from McGill University.